Fax: (525) 528-0095
Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma
Article first published online: 12 JUN 2002
Copyright © 2002 American Cancer Society
Volume 94, Issue 12, pages 3210–3218, 15 June 2002
How to Cite
Arrieta, O., Garcia, E., Guevara, P., Garcia-Navarrete, R., Ondarza, R., Rembao, D. and Sotelo, J. (2002), Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma. Cancer, 94: 3210–3218. doi: 10.1002/cncr.10594
- Issue published online: 12 JUN 2002
- Article first published online: 12 JUN 2002
- Manuscript Revised: 10 DEC 2001
- Manuscript Received: 1 JUN 2001
- Manuscript Accepted: 30 JAN 2001
- National Council of Science and Technology of Mexico. Grant Number: L0001-M9608
- hepatocyte growth factor;
- brain tumors;
Hepatocyte growth factor (HGF) is a cytokine that participates in multiple cell functions; it promotes proliferation, motility, and morphogenesis of epithelial cells. Some malignant tumors, such as breast carcinoma, bronchogenic carcinoma, and multiple myeloma, overexpress it and its receptor. Hepatocyte growth factor is also present in normal astrocytes; therefore, it is important to investigate whether HGF participates in the pathophysiology of malignant gliomas and other brain tumors. Intratumoral concentration of HGF in human intracranial neoplasms was measured and correlated with prognosis, tumor recurrence, vasogenic edema, cell proliferation index, and vascular density.
Hepatocyte growth factor concentration was measured in 62 intracranial tumors, including 16 anaplasic astrocytomas (AA), 16 glioblastoma multiformes (GM), 11 meningiomas, 9 hypophyseal adenomas, 7 oligodendrogliomas, and 3 cordomas, and in 4 samples of nonneoplastic brain tissue. The following parameters were correlated with HGF values: survival and tumor recurrence, cell proliferation index and vascular density as determined by immunohistopathologic analysis, and peritumoral edema as seen by magnetic resonance imaging.
Hepatocyte growth factor concentration (pg/mL) was significantly higher in malignant gliomas (AA and GM) than in adenomas, oligodendrogliomas, and nonneoplastic brain tissue, but it was similar to that of meningiomas. Mean survival of patients with AA was 16.5 ± 3.6 months and for patients with GM 12.3 ± 1.3 months. Hepatocyte growth factor concentration was higher in GM than in AA (15,844 ± 2504 vs. 7499 ± 1703, P = 0.0375) and was correlated with the cell proliferation index and with poor prognosis. Likewise, mean tumoral concentration of HGF was higher in meningiomas that relapsed than in those without recurrence (22,887 ± 6489 vs. 2090 ± 497, P = 0.008).
Intratumoral concentration of HGF in gliomas is associated with malignancy and poor prognosis. High HGF is also found in meningiomas and is related with long term recurrence. The current findings suggest that the routine measurement of HGF may be used as a predictive factor for planning therapeutic strategies in both malignant gliomas and meningiomas. The potential use of HGF inhibitors or antagonists for therapy of these tumors should be explored. Cancer 2002;94:3210–8. © 2002 American Cancer Society.